Korro Bio initiated with an Outperform at William Blair

William Blair analyst Myles Minter initiated coverage of Korro Bio with an Outperform rating and $180 fair value estimate. Korro is a leader in the adenosine deaminase acting on RNA editing field, which aims to perform precise adenosine to inosine substitutions to correct single nucleotide polymorphisms or create de novo proteins of novel function with the goal of disease-modifying therapies, the analyst tells investors in a research note.